Sammita Satyanarayan
Overview
Explore the profile of Sammita Satyanarayan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
101
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Radzik A, Amezcua L, Anderson A, Gilmore S, Ahmad S, Brandstadter R, et al.
Neurology
. 2024 Jan;
102(4):e208100.
PMID: 38261988
Background And Objectives: Racial disparities exist in both neurologic and obstetric populations, underscoring the importance of evaluating pregnancy outcomes in diverse women with multiple sclerosis (MS). The objective of this...
2.
Satyanarayan S, Cutter G, Krieger S, Cofield S, Wolinsky J, Lublin F
Mult Scler
. 2023 Apr;
29(4-5):568-575.
PMID: 37119208
Background: Definitions of trial measures are consequential to accurately capturing outcomes and cross-trial comparability, particularly for derivative measures. Objective: Using CombiRx, examine the impact of relapse definition on endpoints and...
3.
Sand I, Gnjatic S, Krammer F, Tuballes K, Carreno J, Satyanarayan S, et al.
Mult Scler Relat Disord
. 2023 Jan;
70:104486.
PMID: 36628884
Background: People living with multiple sclerosis (MS) and other disorders treated with immunomodulatory therapies remain concerned about suboptimal responses to coronavirus disease 2019 (COVID-19) vaccines. Important questions persist regarding immunological...
4.
Satyanarayan S, Spiegel J, Hovsepian D, Markert M, Thomas R, Muffly L, et al.
Neurohospitalist
. 2022 Dec;
13(1):53-60.
PMID: 36531846
Background And Purpose: Immune Cell Effector Associated Neurotoxicity Syndrome (ICANS) is common amongst patients receiving CD19 targeted Chimeric Antigen Receptor T-cell (CAR-T) therapy. The purpose of this study is to...
5.
Sand I, Gnjatic S, Krammer F, Tuballes K, Carreno J, Satyanarayan S, et al.
medRxiv
. 2022 Jun;
PMID: 35734083
Importance: People living with multiple sclerosis (MS) and other disorders treated with immunomodulatory therapies remain concerned about suboptimal responses to coronavirus disease 2019 (COVID-19) vaccines. Important questions persist regarding immunological...
6.
Satyanarayan S, Safi N, Sorets T, Filomena S, Zhang Y, Klineova S, et al.
Mult Scler Relat Disord
. 2022 May;
62:103737.
PMID: 35533419
Background: Prior studies suggest reduced humoral response to COVID-19 vaccination in immunosuppressed populations. Disease modifying therapies (DMTs) for multiple sclerosis (MS) have variable immunomodulatory effects, and limited data are available...
7.
Rommer P, Milo R, Han M, Satyanarayan S, Sellner J, Hauer L, et al.
Front Immunol
. 2019 Jul;
10:1564.
PMID: 31354720
Multiple sclerosis (MS) is the most common neurological immune-mediated disease leading to disability in young adults. The outcome of the disease is unpredictable, and over time, neurological disabilities accumulate. Interferon...
8.
Satyanarayan S, Kapur A, Azhar S, Yeldandi V, Schneider J
AIDS Behav
. 2014 Nov;
19(6):1031-6.
PMID: 25403143
Little is known about the women connected to Indian MSM and their impact on HIV risk. We surveyed 240 Indian MSM, who identified their social networks (n = 7,092). Women...